About Us

  • 2021

    We cumulatively had penetrated into approximately 2,200 hospitals in the PRC, among which over 1,300 hospitals were Class III hospitals.

    In September, we passed the milestone of 90,000 neuro-interventional procedures using our products (over 5,000 attributable to Tubridge).

    NUMEN and NUMEN FR obtained CE Marking in the European Union in April and FDA registration in the United States and MFDS approval in South Korea in September. The first overseas coil embolization procedure with NUMEN and NUMEN FR was completed in Chile in August, marking NUMEN and NUMEN FR’s entrance to the overseas markets.

    We submitted the NMPA registration application of Neurohawk, our self-developed stent retriever system with enhanced full visualization.

    We further invested in Rapid Medical and became its largest shareholder.

    We completed the 2021 Pre-[REDACTED] Investment with post-money valuation reached US$1.75 billion.

  • 2020

    Our total revenue for the financial year exceeded RMB200 million.

    NUMEN, NUMEN FR, Bridge and U-track were approved by the NMPA and Tigertriever was admitted to the Green Path.

  • 2019

    Our products were used in more than 50,000 neuro-interventional procedures.

    Fastrack was approved by the NMPA.

    We invested in Israel-based Rapid Medical and established a strategic relationship with it, under which we act as the exclusive distributor of Rapid Medical’s flagship products,  Comaneci, Tigertriever, Tigertriever 13 and all follow-up products, in Greater China.

  • 2018

    Our total revenue for the financial year exceeded RMB100 million.

    Tubridge was approved by the NMPA.

    Bridge, the first vertebral artery drug-eluting stent, was admitted to the Green Path.

    We were recognized as one of the Patent Model Enterprises in Shanghai by the Shanghai Intellectual Property Administration.

  • 2017

    We cumulatively had penetrated into approximately 1,000 hospitals in the PRC, among which over 650 hospitals were Class III hospitals.

  • 2016

    Tubridge, the first Chinese-developed flow-diverting stent, was admitted into the NMPA’s innovative medical device special review and approval procedure (known as the “Green Path”).

    We cooperated with Japan-based Asahi Intecc and became the exclusive distributor for Asahi’s neurovascular guidewires in mainland China.

  • 2015

    We were granted ISO 13485 Certification, which demonstrates our commitment to the international standard on product design and development for our production and sales.

  • 2014

    Willis won the Second Prize in National Science and Technology Award  awarded by the State Council of the PRC.

  • 2013

    Willis was approved by the NMPA and became the first and the only stent graft for the treatment of cerebral vessel diseases in the world.

  • 2012

    MP NeuroTech Shanghai, our principal operating subsidiary, was established in Shanghai. Willis won the First Prize in Science and Technology Progress Award of the Ministry of Education of the PRC.

  • 2009

    Willis won the First Prize in Science and Technology Award of Shanghai  awarded by the Shanghai Municipal Government of the PRC.

    APOLLO won the Second Prize in Science and Technology Award of Shanghaiawarded by the Shanghai Municipal Government of the PRC.

  • 2007

    Willis was recognized as one of the innovative medical devices for the treatment of intracranial aneurysm by the Stroke, a journal published by American Heart Association and American Stroke Association.

  • 2004

    Our first product, APOLLO, was approved by the NMPA and became the first approved stent system to treat ICAD in the world.

  • Friendship link
    |   

    Copyright 2019  MicroPort® NeuroTech(Shanghai)Co., Ltd.      Copyright ©  沪ICP备19033024号-1